SG11202011541SA - Chimeric antigen receptor t cell therapy - Google Patents

Chimeric antigen receptor t cell therapy

Info

Publication number
SG11202011541SA
SG11202011541SA SG11202011541SA SG11202011541SA SG11202011541SA SG 11202011541S A SG11202011541S A SG 11202011541SA SG 11202011541S A SG11202011541S A SG 11202011541SA SG 11202011541S A SG11202011541S A SG 11202011541SA SG 11202011541S A SG11202011541S A SG 11202011541SA
Authority
SG
Singapore
Prior art keywords
antigen receptor
chimeric antigen
cell therapy
therapy
chimeric
Prior art date
Application number
SG11202011541SA
Inventor
Adrian I Bot
William Y Go
Yizhou Jiang
John M Rossi
Xiaodong Xue
Original Assignee
Kite Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kite Pharma Inc filed Critical Kite Pharma Inc
Publication of SG11202011541SA publication Critical patent/SG11202011541SA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
SG11202011541SA 2018-06-01 2019-06-03 Chimeric antigen receptor t cell therapy SG11202011541SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862679755P 2018-06-01 2018-06-01
US201862774157P 2018-11-30 2018-11-30
PCT/US2019/035123 WO2019232510A1 (en) 2018-06-01 2019-06-03 Chimeric antigen receptor t cell therapy

Publications (1)

Publication Number Publication Date
SG11202011541SA true SG11202011541SA (en) 2020-12-30

Family

ID=68697134

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011541SA SG11202011541SA (en) 2018-06-01 2019-06-03 Chimeric antigen receptor t cell therapy

Country Status (11)

Country Link
US (1) US20200003758A1 (en)
EP (1) EP3801572A4 (en)
JP (2) JP7174777B2 (en)
KR (2) KR102544086B1 (en)
CN (1) CN112512537A (en)
AU (2) AU2019276592B2 (en)
CA (1) CA3101856A1 (en)
IL (1) IL278992A (en)
SG (1) SG11202011541SA (en)
TW (1) TW202003021A (en)
WO (1) WO2019232510A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230129485A (en) * 2021-01-10 2023-09-08 카이트 파마 인코포레이티드 T cell therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
MX347078B (en) 2010-12-09 2017-04-10 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer.
US9402865B2 (en) 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
KR20140060541A (en) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Rna engineered t cells for the treatment of cancer
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
UY35468A (en) * 2013-03-16 2014-10-31 Novartis Ag CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
EP3102609A4 (en) 2014-02-04 2017-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
CA2986793A1 (en) * 2015-05-28 2016-12-01 Kite Pharma, Inc. Diagnostic methods for t cell therapy
EP3851110A1 (en) 2015-05-28 2021-07-21 Kite Pharma, Inc. Methods of conditioning patients for t cell therapy
EP3307282A4 (en) * 2015-06-12 2019-05-01 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
CA3001613A1 (en) 2015-10-20 2017-04-27 Kite Pharma, Inc. Methods of preparing t cells for t cell therapy
PL3436079T3 (en) 2016-04-01 2021-12-20 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use
EP3484488B1 (en) 2016-07-12 2023-08-09 Kite Pharma, Inc. Antigen binding molecules and methods of use thereof
TWI828334B (en) 2016-09-28 2024-01-01 美商凱特製藥公司 Antigen binding molecules and methods of use thereof
BR112019011065A2 (en) * 2016-12-03 2019-10-01 Juno Therapeutics Inc methods for determining car cell dosage
KR20190104529A (en) * 2016-12-03 2019-09-10 주노 쎄러퓨티크스 인코퍼레이티드 Modulation of CAR-T Cells
ES2900233T3 (en) 2017-02-14 2022-03-16 Kite Pharma Inc Molecules that bind to CD70 and methods of using them
WO2018169922A2 (en) 2017-03-13 2018-09-20 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
JP2020512983A (en) 2017-04-03 2020-04-30 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ Treatment using chimeric receptor T cells containing optimized multifunctional T cells
US10844371B2 (en) 2017-09-22 2020-11-24 Kite Pharma, Inc. Antigen binding molecules and methods of use thereof
CA3076099A1 (en) 2017-09-22 2019-03-28 Kite Pharma, Inc. Linkers for chimeric antigen receptors
WO2019079564A1 (en) 2017-10-18 2019-04-25 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use

Also Published As

Publication number Publication date
TW202003021A (en) 2020-01-16
KR20210014688A (en) 2021-02-09
JP2021525863A (en) 2021-09-27
KR20230093066A (en) 2023-06-26
WO2019232510A1 (en) 2019-12-05
EP3801572A1 (en) 2021-04-14
EP3801572A4 (en) 2022-03-09
AU2019276592B2 (en) 2022-11-24
CA3101856A1 (en) 2019-12-05
CN112512537A (en) 2021-03-16
JP7174777B2 (en) 2022-11-17
AU2023200909A1 (en) 2023-03-23
KR102544086B1 (en) 2023-06-16
US20200003758A1 (en) 2020-01-02
IL278992A (en) 2021-01-31
AU2019276592A1 (en) 2020-12-10
JP2023024996A (en) 2023-02-21

Similar Documents

Publication Publication Date Title
IL272302A (en) Chimeric antigen receptor mediated cell targeting
IL279063A (en) Chimeric antigen receptor t cells (car-t) for the treatment of cancer
EP3286225A4 (en) Cd5 chimeric antigen receptor for adoptive t cell therapy
IL254254A0 (en) Chimeric antigen receptor
GB201503742D0 (en) Chimeric antigen receptor
GB201607968D0 (en) Chimeric antigen receptor
EP3847195A4 (en) Chimeric antigen receptor cells for treating solid tumor
GB201610512D0 (en) Chimeric antigen receptor
ZA202005837B (en) Cd83-binding chimeric antigen receptors
ZA201906321B (en) Chimeric antigen receptor
IL281232A (en) Chimeric antigen receptor for solid cancer and t cells expressing chimeric antigen receptor
IL281428A (en) Chimeric antigen receptor
GB201807870D0 (en) A CD79-specific chimeric antigen receptor
IL280329A (en) Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
IL287440A (en) Antigen specific cd19-targeted car-t cells
GB201801831D0 (en) Chimeric receptor
GB201709508D0 (en) Chimeric antigen receptor
EP4013447A4 (en) Anti-cd83 chimeric antigen receptor expressing t regulatory cells
IL278992A (en) Chimeric antigen receptor t cell therapy
GB201807862D0 (en) Chimeric antigen receptor
EP4106775A4 (en) Chimeric antigen receptor t cell therapy
GB201519900D0 (en) Chimeric antigen receptor
IL308227A (en) Chimeric antigen receptor t cell therapy
GB201815775D0 (en) Chimeric antigen receptor
GB201809773D0 (en) Chimeric antigen receptor